Roche delivers good sales growth in the first nine months of 2016 » FINCHANNEL

The FINANCIAL -- Commenting on the Group’s first nine months, Roche CEO Severin Schwan said: “We had continued good sales growth in both Pharmaceuticals and Diagnostics driven by our newly launched products, and our product pipeline is developing very well. Our cancer immunotherapy medicine Tecentriq has been performing strongly since May, when it was first approved in the US for people with advanced bladder cancer, and it has just received US FDA approval for previously treated metastatic non-small cell lung cancer. Based on our performance so far, I am confident that we will meet our full-year targets for 2016.” The FINANCIAL -- Commenting on the Group’s first nine months, Roche CEO Severin Schwan said: “We had continued good sales growth in both Pharmaceuticals and Diagnostics driven by our newly launched products, and our product pipeline is developing very well. Our cancer immunotherapy medicine Tecentriq has been performing strongly since May, when it was first » The FINANCIAL Pharmacy

Related Keywords

Germany ,Japan ,United States ,France ,America ,Activase Tnkase ,Severin Schwan ,Mabthera Rituxan ,Actemra Roactemra ,Lightmix Zika ,Clinical Laboratory Improvement Amendments ,Pharmaceuticals Division ,Diagnostics Division ,Research In Multiple Sclerosis ,European Society For Medical Oncology ,European Committee For Treatment ,International Region ,Tissue Diagnostics ,North America ,European Committee ,Multiple Sclerosis ,European Society ,Medical Oncology ,Respiratory Syncytial Virus ,Emergency Use Authorization ,Accu Chek Guide ,Dow Jones Sustainability Index ,Pharmacy ,